Expression of immunoglobulin (Ig), a marker characteristic of B cells, has been reported in epithelial cells and has been suggested to have a role in their survival and growth. We assessed the frequency and level of Ig gamma heavy chain (IgG) expression in acute myeloid leukemia (AML), and found that IgG was expressed at a high frequency and level in AML cell lines and primary myeloblasts, but not in monocytes or neutrophils from patients with non-hematopoietic neoplasms or healthy controls. AML-derived IgG had the same molecular weight as B cell-derived IgG and was secreted. We further detected IgG V H DJ H transcripts in AML cell lines and sorted primary myeloblasts, confirming that IgG expression was indeed produced by AML cells. AML-derived IgG gene rearrangements showed evidence of somatic hypermutation of the variable (V) gene segments, and restricted (AML cell lines) or biased (primary myeloblasts) V usage. Anti-human IgG reduced cell viability and induced apoptosis in AML cell lines. Although the function of the AML-derived IgG is unclear, our findings suggest that AML-derived IgG may be a novel AML-related gene that contributes to leukemogenesis and AML progression. AML-derived IgG may serve as a useful molecular marker for monitoring minimal residual disease or designing target therapy.
INTRODUCTION
Immunoglobulin (Ig) was previously thought to be produced only by B lymphocytes and plasma cells. During the past decade, however, this concept has been challenged by a series of studies. Different types of Ig, including IgG, IgM and IgA, have been shown to be expressed in many types of neoplastic epithelial cells, including those arising in the breast, colon, lung, liver, neck and mouth. In these cells, Ig is present in both membranous and secreted forms, similar to B cell-derived Ig. [1] [2] [3] [4] [5] [6] Subsequently, Ig expression has been detected in several types of nonhematopoietic cells from healthy individuals, including epithelial cells, germ cells, neurons and myocardial cells. [7] [8] [9] In addition, Ig expressed in these normal cells shows some unique characteristics, including restricted usage of certain sequences, 9 ,10 a unique glycosylation profile 11, 12 and different regulatory mechanisms of gene expression than are known in B cells. 13, 14 Moreover, it has been shown recently that nonhematopoietic cell-derived Ig is involved in cell survival and proliferation. 1, 5 These findings suggest that non-hematopoietic cell-derived Ig is a novel molecule with a unique structure and function that may have a role in carcinogenesis.
Myeloid cells originate from hematopoietic stem cells in the bone marrow. It has been believed that myeloid cells cannot produce Ig. In this study, we sought to explore whether acute myeloid leukemia (AML) cells (myeloblasts) as well as other cells of myeloid origin, that is, mature normal monocytes and neutrophils, could produce Ig. We also sought to determine differences in Ig expression between these cells that might have clinical utility. Our results show for the first time that IgG is expressed and secreted in AML cell lines and primary myeloblasts at a high frequency and level. We also found that IgG V H DJ H was rearranged only in AML cells, but not in monocytes or neutrophils. Furthermore, the AMLderived IgG Variable (V) region revealed somatic hypermutation and a restricted or biased usage of certain V segments. Preliminary functional study showed that anti-human IgG reduced cell viability and induced apoptosis in AML cell lines in culture. These results suggest that AML-derived IgG may have a role in AML pathogenesis and progression, and potentially could serve as a novel molecular marker for the monitoring of minimal residual disease and development of target therapy.
CD33
þ cells. To analyze IgG V H DJ H gene transcription in CD33 þ AML cells, we assessed peripheral blood specimens from another 15 AML patients. We also analyzed IgG V H DJ H gene transcription in CD33 þ adult monocytes and neutrophils derived from peripheral blood specimens of 15 patients with non-hematopoietic neoplasms as well as 10 healthy individuals. The clinicopathologic data were obtained by review of medical records.
Molecular genetic analyses
Karyotypic analysis was performed on metaphase cells prepared from bone marrow aspirate specimens using standard techniques. 15 The results were reported using the 2005 International System for Human Cytogenetic Nomenclature.
Genomic DNA extracted from bone marrow aspirate specimens was amplified by PCR and subjected to mutational analysis for codons 12, 13 or 61 of KRAS and NRAS by pyrosequencing using a PSQ HS 96 Pysosequencer (Biotage, Uppsala, Sweden), 16 or KIT (exons 8 and 17) and CEBPA by direct Sanger sequencing on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). 16, 17 A fluorescence-based multiplex PCR followed by capillary electrophoresis was used to detect internal tandem duplication and D835 point mutation of the FLT3 gene and exon 12 mutation of the NPM1 gene using genomic DNA and an ABI Prism 3100 Genetic Analyzer. 18, 19 Flourescence-activated cell sorting For sorting of myeloblasts from AML patients, mononuclear cells were isolated from peripheral blood by Ficoll-Hypaque density gradient centrifugation, and washed with 0.01M PBS. The mononuclear cells were stained with monoclonal antibodies specific to CD19 (APC, BD Pharmigen, San Diego, CA, USA), CD33 (FITC, BD Pharmigen) and CD138 (PE, BD Pharmigen) at 4 1C for 15 min. After washing twice with PBS, the cells were sorted using a FACScan instrument (BD Pharmigen).
þ cells also were collected and used as a positive control. Anti-mouse IgG1-PE was used as an isotype control.
For sorting of monocytes and neutrophils, erythrocytes from patients with non-hematopoietic neoplasms and healthy individuals were lysed by incubating 1 ml of peripheral blood with 8 ml of distilled water for 30 s. Following lysis, 1 ml of 10 Â PBS was added and centrifugation was performed at 1500 r.p.m. for 5 min. The supernatant was discarded, and leukocytes were washed twice with PBS, before 1 Â 10 6 leukocytes were stained with monoclonal antibodies specific to CD19 (APC), CD33 (FITC) and CD138 (PE), washed and sorted. Monocytes and neutrophils were gated by using forward versus side scatter dot plots. The CD33 þ CD19 À CD138 À cells in both populations were selected. CD33 À CD19 þ cells also were collected and used as a positive control. Anti-IgG-PE was used as an isotype control.
Immunocytochemistry
Cytospin preparations were prepared from AML cell lines. The slides were fixed with 100% acetone for 5 min, incubated with 1% hydrogen peroxide for 10 min, washed with PBS, and then blocked with PBS containing 10% goat serum for 10 min. Excess blocking buffer was removed. Indirect immunohistochemical staining was performed by incubating the slides with monoclonal anti-human IgG (2 ng/ml, Sigma, St Louis, MO, USA) or an antibody against human cancer-derived IgG, RP215 (2 ng/ml, a gift from Dr G Lee, the University of British Columbia, Vancouver, Canada) in a 37 1C humidified chamber for 45 min. After washing, the slides were incubated with anti-mouse IgG-horseradish peroxidase (HRP; Dako, Carpinteria, CA, USA) at room temperature for 20 min. The slides were washed, and bound antibodies were detected using 3,3 0 -diaminobenzidine tetrahydrochloride (DAB; Dako) according to manufacturer's instructions.
Immunoprecipitation and western blot analysis Primary or cultured AML cells were lysed with radioimmunoprecipitation assay lysis buffer (Thermo Fisher Scientific Inc., Rockford, IL, USA) on ice for 15 min, and centrifuged at 15 000 r.p.m. for 15 min. The lysate was incubated with monoclonal anti-human IgG (Sigma), or mouse IgG1 (as an isotype control, Sigma), and protein G/A-beads (Abcam, Cambridge, MA, USA) for 30 min. After centrifugation at 12 000 r.p.m. for 5 min, the supernatant was removed and the lysate was washed twice. The antigen-antibody complex was eluted followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blot analysis using goat anti-human IgG (1:2000; Sigma) as the primary antibody, rabbit anti-goat 
À cells, total RNA was extracted using the RNeasy Micro Kit (Qiagen Inc., Chatsworth, CA, USA) according to manufacturer's instructions. Reverse transcription (RT) was performed using the Sensiscript RT Kit (Qiagen Inc.). IgG V H DJ H transcripts were detected by a nested PCR. The primers and conditions for the first-round PCR for the amplification of V H DJ H were described previously. 10 For the second-round PCR, an upstream primer that anneals to the framework 2 (FR2) region (FR2:
, coupled with a JH primer (JH: 5 0 -AACTGCAGAGGAGACGGTGACC-3 0 ), was used. 20 The amplification products were gel-purified using a DNA purification column (Qiagen Inc.), ligated into the pCR2.1 vector (Invitrogen), and transformed into DH5a-competent bacteria (Invitrogen). In all, 5-10 colonies per sample were chosen randomly, and sequenced using the T7 primer (Invitrogen).
Analysis of rearranged IgG V H DJ H genes
The rearranged V H DJ H sequences were compared with those in the basic local alignment search tool (BLAST, http://www.ncbi.nlm.nih.gov/BLAST) and Immunogenetics (http://www.imgt.org/) databases to identify the best matching germline gene segments and junctions. For the analysis of somatic hypermutation, the part of the IgG V region from FR2 to JH was used. Mutation status was designated as unmutated if there were fewer than 2% mutations (498% homology to germline sequences), or as mutated if there were 2% or more mutations (p98% homology to germline sequences) compared with the germline sequences. 21 
Effect of anti-human IgG on viability and apoptosis of AML cell lines
We performed a cell viability assay using the Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Inc., Kumamoto, Japan). HL-60 and OCI-AML3 cell lines were plated in a 96-well plate at 1 Â 10 5 cells/well, and incubated in DMEM (Sigma) supplemented with 10% fetal bovine serum at 37 1C overnight. The supernatant was then discarded, and goat anti-human IgG (25 mg/ml; Sigma) or goat IgG (isotype control, 25 mg/ml; Sigma) was added. The cells were then incubated as mentioned above, and cell viability was assessed using the CCK-8 kit at 24, 48, 72 and 96 h.
We evaluated the effect of anti-human IgG on apoptosis of AML cell lines. HL-60 and OCI-AML3 cell lines were plated in a six-well plate at 5 Â 10 5 cells/well, and incubated in DMEM (Sigma) supplemented with 10% fetal bovine serum at 37 1C overnight. The supernatant was then discarded, and goat anti-human IgG (25 mg/ml; Sigma) or goat IgG (isotype control, 25 mg/ml; Sigma) was added. The cells were then incubated as mentioned above, and apoptosis was assessed using annexin V/propidium iodide staining at 72 h.
Statistical analyses
Statistical analyses were performed using SAS 8.1 (SAS Institute Inc., Cary, NC, USA). Differences between groups were evaluated using Student's t-test or the w 2 -test. A P-value of o0.05 was considered statistically significant.
RESULTS

Clinicopathologic features
Fourteen AML patients were evaluated for membranous IgG expression by CD33 þ myeloblasts (Table 1 ). There were 10 men and 4 women with a median age of 62 years (range, 7-85 years). The diagnoses using current World Health Organization terminology included: six cases of AML with myelodysplasiarelated changes (AML-MRC), three cases of AML with maturation (M2), two cases of AML without maturation (M1), two cases of acute myelomonocytic leukemia (M4) and one case of acute monocytic leukemia (M5). The bone marrow blast count ranged from 26 to 92% (median, 67%). All patients received multi-agent chemotherapy; five also were treated with allogeneic stem cell transplantation. With a median follow-up of 17 months (range, 3-69 months), nine patients died of disease, three patients had persistent disease and two were in complete remission after transplantation (Table 1) .
Conventional cytogenetic analysis showed a complex karyotype (X3 abnormalities) in 5 patients, 1-2 cytogenetic abnormalities in 5 patients and a diploid karyotype in 4 patients. Molecular analysis revealed internal tandem duplication of the FLT3 gene in 6/14 (43%) cases, and mutations in CEBPA, NPM1 and KRAS in 1/4 (25%), 1/10 (10%) and 1/12 (8%) cases, respectively. None of the 12 cases assessed had NRAS or KIT mutations.
Subsequently, another 15 AML patients were assessed for IgG V H DJ H gene transcription in sorted CD33
þ AML cells, which included 5 cases of AML-MRC, 3 cases of AML-M4, 2 cases of AML-M1, 1 case each of AML with t(15;17)(q22;q21), AML-M2 or AML-M5, and 2 cases of relapsed AML, not further classifiable (Table 2) .
We also analyzed CD33 þ monocytes and neutrophils from 15 patients with non-hematopoietic neoplasms and 10 healthy individuals for IgG V H DJ H gene transcription. The group of patients with non-hematopoietic neoplasms included five with colorectal adenocarcinoma, three with squamous cell carcinoma of the tongue (n ¼ 2) or tonsil (n ¼ 1), two with stomach adenocarcinoma and one each with hepatocellular carcinoma, pancreatic adenocarcinoma, high-grade sarcoma, glioblastoma or thymoma (Table 2) .
Immunoglobulin gamma heavy chain is expressed in AML cell lines and primary myeloblasts To determine if IgG is expressed in AML cells, we first performed immunohistochemical studies using a monoclonal antibody against human IgG in six AML cell lines: HEL, NB4, HL-60, KG-1, OCI-AML3 and THP-1. We observed strong IgG expression in all six AML cell lines assessed (Figure 1a) .
We performed two-color flow cytometry immunophenotyping using anti-human IgG-PE and anti-human CD33-FITC on peripheral blood mononuclear cells from AML patients, and demonstrated IgG expression in primary CD33
þ myeloblasts in 11 of 14 AML patients assessed. IgG was expressed on 33-100% of CD33 þ myeloblasts (median, 93%) from AML patients (Table 1; Figure 1b) . AML-derived IgG has the same molecular weight as B cell-derived IgG and is secreted Immunoprecipitation and western blot analysis confirmed the presence of IgG in AML cell lines and primary myeloblasts. In addition, the AML-derived IgG had the same molecular weight as classic IgG expressed by B lymphocytes (Figure 1c) .
We collected supernatants from cell cultures of AML cell lines and patient myeloblasts at 0, 24, 48, 72 and 96 h, and assessed 
Data shown as median (range).
IgG gene expression in acute myeloid leukemia X Qiu et al them for the presence of IgG by enzyme-linked immunosorbent assay. We detected the presence of IgG in the supernatant of AML cell cultures in both AML cell lines and primary myeloblasts, and showed that the level of secreted IgG was significantly higher at 72-96 h in culture than at 0 h (Po0.001; Figure 1d ).
IgG V H DJ H transcripts are detected in AML cell lines and primary myeloblasts but not in non-neoplastic monocytes and neutrophils We performed cell sorting by flow cytometry on peripheral blood mononuclear cells (Figure 2A, P1 ) from AML patients using monoclonal antibodies specific for CD19 (APC), CD33 (FITC) and CD138 (PE) to isolate CD33 þ CD19 À CD138 À myeloblasts (Figure 2A, P4) . CD19 þ CD33 À cells (Figure 2A , P3) also were collected and used as a positive control. We also isolated CD33 We performed RT-PCR using primers specific to the FR2 and JH regions of IgG V H DJ H on AML cell lines, sorted CD33 þ CD19 À CD138 À primary myeloblasts from AML patients, and sorted
À adult monocytes and neutrophils from patients with non-hematopoietic neoplasms and healthy individuals. CD19 þ B cells from patients with non-hematopoietic neoplasms and healthy individuals were used as a positive control. We detected IgG V H DJ H transcripts in 5 of 6 AML cell lines (all except KG-1; Figure 2C ), CD33 þ myeloblasts from 6 of 15 AML patients assessed (Figure 2Da) , and CD19 þ B cells from patients with non-hematopoietic neoplasms and healthy individuals (Figure 2Db ). IgG V H DJ H transcripts were not detected in monocytes or neutrophils from patients with non-hematopoietic neoplasms or healthy individuals, however (Figure 2Dc ).
IgG V H DJ H rearrangements demonstrate restricted or biased usage of V segments AML cell line-derived IgG V H DJ H rearrangements displayed restricted usage of a unique sequence in four of five AML cell lines assessed (except NB4). All showed VH3-48/D4-7/JH4 rearrangement (Figure 3a) . Moreover, high homology, including the same complementary determining region 3 sequence, was identified in the VH3-48/D4-7/JH4 rearrangement from different AML cell 
DISCUSSION
In this study, we report for the first time that the IgG gene is transcribed and expressed at a high frequency and level in AML cell lines and primary myeloblasts, but not in adult non-neoplastic monocytes or neutrophils. Moreover, IgG V H DJ H rearrangements from AML cells have undergone somatic hypermutation and display restricted or biased usage of V segments. Anti-human IgG reduces cell viability and induces apoptosis in AML cell lines in culture. These findings suggest that IgG gene expression in AML cells is not random, and may therefore have a role in either leukemogenesis or AML progression.
For nearly a century, B lymphocytes have been considered to be the only source of Ig. It has been assumed that other types of cells, including other hematopoietic cells, could not produce Ig. In keeping with this concept, monoclonal Ig gene rearrangement has been used as a diagnostic tool for B-cell lymphomas. In recent years, however, there has been a growing realization that Ig can be expressed in other types of cells, such as epithelial cells, neurons and germ cells, and especially in many types of epithelial cancer cells. [1] [2] [3] [4] [5] [6] [7] [8] [9] Expanding this concept, our results demonstrated that IgG is often expressed in AML cell lines and primary myeloblasts. More importantly, the AML-derived IgG was secreted into the supernatant of cell cultures. In addition, our results showed that AML-derived IgG has the same molecular weight as that produced in B lymphocytes.
There have been a few reports of Ig gene expression, albeit at low frequency, in bone marrow or peripheral blood specimens from patients with AML. 22 In these reports, it remained unknown, however, whether Ig was produced by myeloid-derived hematopoietic cells, for example, myeloblasts, or was secreted by residual B cells that were present in the samples. It also was not clear if Ig was transcribed and translated or if this was due to nonspecific binding of Ig produced by residual B cells. Furthermore, Ig expression in primary myeloid-derived cells in a natural state in vivo, for example, in non-neoplastic monocytes and neutrophils, has not been studied. To address these questions, we investigated IgG gene rearrangement and transcription in sorted CD33 þ
CD19
À CD138 À myeloblasts from patients with AML as well as adult monocytes and neutrophils from patients with nonhematopoietic neoplasms and healthy controls. After confirming that there were no residual B cells or plasma cells in the samples by flow cytometric analysis, we performed RT-PCR using primers that are specific to IgG V H DJ H genes. We successfully detected the V H DJ H transcripts in CD33 þ myeloblasts in 6 of 15 AML patients, but not in CD33 þ monocytes or neutrophils from patients with non-hematopoietic neoplasms or healthy controls. These results confirm that the expression of IgG detected by immunohistochemistry and flow cytometry in myeloid cells is indeed produced by myeloblasts, rather than non-specific membranous binding of IgG that is secreted by residual B cells in the sample.
During the past decade, several groups have suggested that IgG is involved in epithelial carcinogenesis. 1, 5, 6 Although the function of the AML-derived IgG is still unclear, our preliminary results showed that anti-human IgG blocked the activity of IgG in AML cell lines, HL-60 and OCI-AML3, reduced cell viability and induced apoptosis. These findings suggest that AML-derived IgG has a role in AML pathogenesis. We also have attempted to compare the diagnostic classification and clinical outcome between AML patients with and without expression of V H DJ H transcripts. Although no significant differences were observed, the number of patients included in this study is too small to draw any definitive conclusions.
Interestingly, sequence analysis of AML-derived IgG showed evidence of somatic hypermutation. Moreover, IgG V H DJ H rearrangements from AML cell lines displayed restricted usage of a unique sequence; all showed VH3-48/D4-7/JH4 rearrangement. However, IgG V H DJ H rearrangements from primary myeloblasts displayed diversity, similar to B cell-derived IgG, though with a biased usage of VH3 and VH4 segments. We do not have a satisfactory explanation for the apparent discrepancy in V, D and J usage between primary myeloblasts and AML cell lines. It is possible that the restricted usage of V, D and J segments in AML cell lines is a result of secondary rearrangement induced by identical cell culture conditions. In summary, we have shown that the IgG gene is transcribed, expressed and secreted in both AML cell lines and primary myeloblasts. As this does not occur in non-neoplastic adult monocytes or neutrophils, AML-derived IgG may have a role in AML pathogenesis and progression. The presence of AML-derived IgG, in either cell-bound or secreted forms, may be used as a marker for monitoring of minimal residual disease in AML patients after chemotherapy. Moreover, the fact that anti-human IgG can inhibit growth in AML cell lines suggests that IgG may serve as a potential target for AML therapy.
